Andrew Pumerantz, DO, FACP
Executive Director, Western Diabetes Institute, Associate Professor of Internal Medicine / Chief, Division of Infectious Disease
College of Osteopathic Medicine of the Pacific
Phone: 909-706-3779 | Fax: 909-620-1048
Join year: 2007
Andrew S. Pumerantz received an AB in 1984 from Occidental College and his DO degree with honors in 1988 from Philadelphia College of Osteopathic Medicine. In 1992, Dr. Pumerantz completed Internal Medicine residency at Beth Israel Medical Center in New York City and then served another year as a Chief Medical Resident. In 1995, he completed Infectious Diseases fellowship at Yale University School of Medicine and for 12 years practiced consultative ID in the New York City Metro area. In 2007, Dr. Pumerantz arrived at WesternU as Associate Professor of Internal Medicine and COMP’s Division Chief of Infectious Disease. He initiated sweeping curricular changes moving from traditional lecture-based delivery to a more case-based and interactive learning design to foster critical-thinking and diagnostic acumen. He redesigned the infectious disease components and helped guide the broader internal medicine curricular redevelopment. In 2008 with WesternU pharmaceutical scientists, Drs. Jeffrey Wang and Guru Betageri, Dr. Pumerantz co-invented PEGylated liposomal vancomycin (PLV) and spent 5 years as the cross-disciplinary team’s Principal Investigator evaluating its biodistribution and drug delivery in treating MRSA pneumonia. From 2008 to 2012, Dr. Pumerantz served as Department Chair of Internal Medicine during which time he established the Divisions of Endocrinology, Diabetes, and Metabolism; Nephrology and Hypertension; Infectious Disease; and Cardiovascular Disease. In 2012, Dr. Pumerantz received the first COMP Faculty Award for Outstanding Cross Campus Colleague. During his tenure as Internal Medicine Chair, he established the Western Diabetes Institute (WDI). The WDI was designed as an integrated practice unitorganized around diabetes and its co-occurrences whose mission is to deliver measurably high-value, patient-centric and cross-disciplinary, team-based care across the total cycle. As part of a disruptive innovation in health care delivery, all patients referred by their primary care provider to the WDI with a diagnosis of diabetes undergo an initial same-day comprehensive multidisciplinary evaluation from which a more granular diagnosis can be made that takes into account the phenotypic heterogeneity of the condition. The Diabetes Cross-Disciplinary Index(DXDI©), an assessment tool developed by Dr. Pumerantz at the WDI, is a 10-dimension, 5-level composite disease severity and complexity schema that reframes diabetes and provides each patient with their phenotypic diagnostic profile. Their DXDI© profile (one of a potential 452 combinations) serves as a shared decision-making tool, balanced scorecard, and lingua franca for the “collaborative therapeutic alliance” of patient, caregiver, and multidisciplinary provider team. Enabling improved patient engagement, DXDI© enhances the alliance’s ability to recognize disease patterns and deliver more precise, personalized, and coordinated care in alignment with the patient’s own health goals. In 2012, the WDI was re-organized into a freestanding interprofessional WesternU entity and now consists of the Endocrine and Insulin Titration Clinics; Heart and Vascular Center; Center for Kidney Disease and Hypertension; Center for Fitness and Function; Diabetes Education and Nutrition Unit; Infectious Disease Clinic; Behavioral Health Unit; Care Coordination Unit; and Clinical Research Unit. The WDI also collaborates with the Dental and Eye Care Centers of WesternU. As a research institution, WDI is actively studying the science of diabetes care delivery and maintains an IRB-approved Diabetes Disease Registry.Dr. Pumerantz has spoken internationally on PLV and disruptive innovation in diabetes care. He maintains American Board of Internal Medicine certification in both Infectious Disease and Internal Medicine.
Pumerantz A, Muppidi K, Agnihotri S, Guerra C, Venketaraman V, Wang J, Betageri G. Preparation of liposomal vancomycin and intracellular killing of meticillin- resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents 2011; 37: 140-144
Muppidi K, Wang J, Betageri G, Pumerantz AS. PEGylated Liposome Encapsulation Increases the Lung Tissue Concentration of Vancomycin. Antimicrob Agents Chemother 2011; 55(10): 4537-4542.
Muppidi K, Pumerantz AS, Wang J, Betageri G. Development and Stability Studies of Novel Liposomal Vancomycin Formulations. ISRN Pharmaceutics 2012; Volume 2012, doi:10.5402/2012/636743
Pumerantz AS. PEGylated Liposomal Vancomycin: A Glimmer of Hope for Improving Treatment Outcomes in MRSA Pneumonia.Recent Pat Antiinfect Drug Discov 2012; Vol. 7, No. 3: 205-212.
Muppidi K, Pumerantz AS, Betageri G, Wang J. Development and Validation of a Rapid High-Performance Liquid Chromatography Method with UV Detection for the Determination of Vancomycin in Mouse Plasma.J Chromat Separation Techniq 2013; 4: 165.